Matrix metalloproteinases (MMPs) play important roles in the pathophysiology of cerebral ischemia. Here we visualized in vivo MMP activity in the transient middle cerebral artery occlusion (tMCAO) mouse model using multispectral optoacoustic imaging (MSOT) with a MMP-activatable probe. MSOT data was co-registered with structural magnetic resonance imaging (MRI) obtained at 7 T for localization of signal distribution. We demonstrated upregulated MMP signal within the focal ischemic lesion in the tMCAO mouse model using MSOT/MRI multimodal imaging. This convenient non-invasive method will allow repetitive measurement following the time course of MMP-lesion development in ischemic stroke animal model.
INTRODUCTION
Stroke is the second leading cause of death and disability in the Western world. Ischemic stoke involves a cascade of hemodynamic, vascular, and inflammatory responses that evolve in a time-dependent manner [1] [2] [3] . Inflammation is implicated in the initial neuronal loss and extension of the lesion in the penumbra, and in the subsequent functional recovery. MMPs are a class of proteases that are involved in the inflammatory processes. The upregulated activities of MMPs have been shown important and differential roles in the pathophysiology after stroke. MMPs inhibitors show distinct protective or lesion exacerbating effects on the ischemic lesion in animal model of cerebral ischemia, depending on the time point of treatment, ie. acute versus chronic treatment [4, 5] . Thus it is critical to develop non-invasive diagnostic tools for monitoring the levels of MMPs in the brain, in order to determine appropriate treatment paradigm for ischemic stroke [6] . Different methods such as positron emission tomography (PET) [7] as well as near-infrared fluorescence (NIRF) imaging [8] with probes targeting at MMPs have been applied to investigate non-invasively in mouse and rat models of cerebral ischemia. Upregulated levels of MMP were reported in mouse focal ischemic model after 18 h until 72 h after reperfusion compared with sham-operated control by using NIRF imaging with a MMPactivatable probe [8] . However, the PET imaging has the constrains of radiotracer availability and limited resolution; while the planar NIRF imaging is limited by a poor spatial resolution and lack of depth-dependent quantification due to the scattering nature of light propagation in living tissue.
Multispectral optoacoustic tomography (MSOT) allows the non-invasive assessment of photoabsorbing molecules relatively deep in tissue [9] in brains of rats and mice [10] . MSOT resolves signal contribution from different photoabsorbing molecules in tissue simultaneously based on their spectral properties [11] . Here we provide a novel noninvasive estimate of MMP activity in the ischemic lesion region using a MMP-activatable probe and MSOT in the tMCAO mouse model of cerebral ischemia and reperfusion. Ischemic lesion size was assessed in vivo using structural T 2 -weighted MRI. Elucidating the spatio-temporal evolution of inflammatory processes in the brain in vivo will facilitate the understanding of mechanism underlying cerebral ischemia.
METHODS

Animal model
All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich (permit number: ZH 26416). All procedures fulfilled the ARRIVE guidelines on reporting animal experiments. Thirteen male C57BL/6J mice (Janvier, France), weighting 20-25 g, 10-weeks-of-age were included in the study. Nine mice underwent tMCAO surgery, and four mice underwent sham-operation as described before [12] . During surgery, mice were given local analgesia and kept under isoflurane anaesthesia, maintaining the body temperature at 36.5 ± 0.5 °C. Six tMCAO mice and four sham-operated mice were injected intravenously with 300 μl (4 nM) of MMP-activatable probe (MMPSense TM 680, Perkin Elmer, U.S.A.) after 1 h of tMCAO. Three tMCAO mice without MMP probe injection were assessed and served as controls of endogenous tissue changes. At 48 h after reperfusion, all animals were assessed with in vivo MSOT for detecting MMP activity, in vivo T 2 -weighted MRI for estimating the lesion size in the brain, ex vivo NIRF imaging and viability staining of the mouse brain slices.
MSOT imaging of MMP activity in phantom and in mouse model
MMP-activatable probe was incubated with human recombinant MMP-9 or trypsin in vitro and the solution was placed in an agar phantom. A MSOT inVision 128 imaging system (iThera Medical, Germany) was used as described previously [12] . Briefly, a tunable (680-980 nm) optical parametric oscillator pumped by an Nd:YAG laser provides 9 ns excitation pulses at a framerate of 10 Hz with a wavelength tuning speed of 10 ms and a peak pulse energy of 100 mJ at 730 nm. Ten arms, each containing an optical fiber bundle, provide even illumination of a ring-shaped light strip with a width of approx. 8 mm. For ultrasound detection, 128 cylindrically focused ultrasound transducers with a center frequency of 5 MHz (60 % bandwidth), organized in a concave array of 270 degree angular coverage and a curvature radius of 4 cm, were used.
For phantom measurements, the phantom was fixed into the supplied rigid phantom holder and placed into the imaging chamber of the MSOT system. Phantom measurements using different concentrations of trypsin mixed with MMP activatable probe were used to generate the absorbance spectra. After equilibrating the temperature of the phantom for 5 min, imaging was performed at 45 wavelengths from 680 to 900 nm with 5 nm increments. Principle component analysis based on [13] was used for calculating the absorbance spectra of MMP which was later used in the spectral unmixing for tMCAO/ sham-operated data. For in vivo MSOT measurements, animals were anesthetized under 1.5 % isoflurane in a 1:4 oxygen/air mixture supplied via a nose cone and were warmed to main body temperature at 36.5 °C. Mice were depilated around the head and placed in a mouse holder in supine position. Pre-heated ultrasound gel (Diagramma, Switzerland) was applied to the mouse head and the animals were wrapped in a polyethylene membrane. The mouse holder was placed in an imaging chamber filled with 36.5 °C water. Images were acquired at 10 wavelengths (680, 685, 690, 695, 700, 715, 730, 760, 800, and 850 nm), for 35-40 consecutive slices with a step size of 0.3 mm and 10 averages.
MRI
Data was acquired on a 7 T Bruker Pharmascan (Bruker BioSpin GmbH, Germany), equipped with a volume resonator operating in quadrature mode for excitation and a four element phased array surface coil for signal reception. Mice were kept under 1.5 % isoflurane anesthesia in a 1:4 oxygen/air mixture and body temperature at 36.5 ± 0.5 °C using a warm water circuit integrated into the animal support (Bruker BioSpin GmbH, Germany). T 2 -weighted MR images were obtained using a spin echo sequence (TurboRARE) with echo time = 3 ms, repetition time = 6 ms, 100 averages, slice thickness = 1 mm, field of view = 2.56×1.28 cm 2 , matrix size = 256×128, giving an in-plane resolution = 100 µm×100 µm. Lesion and edema size was determined on T 2 -weighted images. The Paxinos mouse brain atlas was used as the anatomical reference for MRI scan and analysis.
NIRF imaging
NIRF imaging was performed with the Maestro 500 multi-spectral imaging system equipped with a band pass filter (615 to 665 nm) for excitation (Cambridge Research & Instruments Inc., USA) as previously described [8] . After in vivo assessment, mouse brain was cut coronally using a Brainmatrix into 6 or 7 brain tissue slices of 1-mm thickness. For ex vivo NIRF imaging, the coronal brain slices were imaged using a CCD camera fitted with a long pass filter (> 700 nm) by automatically increasing the emission filter wavelengths at 10 nm steps. Regions of interest (ROIs) were selected over different regions of the brain slices. Fluorescence intensity (F.I.) ratios were calculated by dividing the ROI values of the left ischemic (ipsi-lateral) hemisphere by that of the right (contra-lateral) hemisphere.
Triphenyl tetrazolium chloride (TTC) staining
After ex vivo NIRF imaging brain slices were incubated in a 2.5 % TTC solution (Sigma-Aldrich, Switzerland) at 37 °C for 3 min. Images of brain sections were taken and analyzed by drawing ROI over the ipsi-lateral side and the nonischemic contra-lateral side using ImageJ. Edema corrected cerebral lesion volumes were calculated by summing up the area of each sides and dividing the area of the ipsi-lateral by the contra-lateral side.
MSOT image reconstruction, spectral unmixing
MSOT images were reconstructed using a model based linear algorithm (size 20 mm, resolution 100 μm, filter range 50.0 kHz-7 MHz). For the multispectral processing, linear regression unmixing methods (850 nm background) with a non-negative constraint imposed during inversion was applie.
MRI-MSOT co-registration and image analysis
We adopted a two-step strategy to register the resulting unmixed MSOT images and structural MRI images using Matlab (R2015a, Mathworks, USA). The first step was the selection of landmarks. With the assumption that the longitudinal axes for the same object in MSOT and MRI images were parallel, one slice of the MSOT images and one slice of MRI images were picked. In these two slices, at least seven pairs of anatomical landmarks such as the eyes or neuroanatomical structures were selected for alignment. Secondly, a non-reflective similarity transformation was calculated based on the selected landmarks in the MSOT and MRI images. Rotation, scaling and transformation have been taken into account while angles and shapes were preserved during registration. Finally, the registration results were visualized by overlapping different components of MSOT images with the corresponding MR structural reference image using ImageJ (NIH, U.S.A.). ROIs were delineated on coronal cross-sections view at the ipsi-, contra-lateral side over the cortex and striatum of the mouse brain.
Statistics
All data are present as mean ± standard deviation (SD). Non-parametric Mann-Whitney unpaired student t test was used for comparison between tMCAO and sham-operated mice (Graphpad Prism 6.0, CA, U.S.A). Significance was set at * p < 0.05, ** p < 0.01, *** p < 0.001.
RESULTS
Co-registration of MSOT and MRI
MSOT has inherently low soft tissue contrast and cannot demarcate the ischemic lesion, therefore we decided to use T 2 -weighted MRI in conjunction with MSOT. Landmark co-registration method was used to inform lesion related ROI analysis of MSOT data. 
MMP MSOT absorbance spectra analysis
MMP MSOT absorbance spectra was generated by phantom measurements using different concentrations of trypsin mixed with the MMP-activatable probe. Principle component analysis based on [13] was used for calculating the absorbance spectra of the probe (Figure 2 ). The spectra was later used in the multispectral analysis of the data obtained from measurements of tMCAO and sham-operated mice. 
MMP MSOT in tMCAO mouse during occlusion
MSOT measurements were performed in the tMCAO and sham-operated mice at 48 h after reperfusion. In tMCAO mouse MMP activity was observed in the ischemic lesion delineated on T 2 -weighted MR images compared to contralateral hemisphere and sham-operated animals at 48 h after reperfusion (Figure 3 ). Extracerebral MMP activity was observed in animals likely caused by muscle damage that is caused by the ligation of the extracarotid artery which is required in the tMCAO model [12] In non-injected tMCAO mice, no MMP signal was observed over the lesion. We quantified the lesion size in tMCAO mice in vivo using T 2 -weighted MRI at 48 h after reperfusion and ex vivo using TTC staining (Figure 4) . 
DISCUSSION
The pathophysiology of ischemic stroke is complex, involving a series of cellular and molecular events where hemodynamic alterations and inflammation play a prominent role in ischemic tissue damage [14] . We demonstrated the feasibility of MSOT for in vivo detection of MMP activity, and shown that the signal is predominantly located in the ischemic ipsi-cortex and striatum of tMCAO mouse brain. Ex vivo NIRF imaging on the brain sections validated the finding that MMP signal is confined in the ipsilateral ischemic hemisphere of the mouse brain.
There are several considerations in the current study. 1) Co-registration: deformative co-registration and fiducial marker based co-registration algorism will provide more accuracy compared to the landmark method used in the current approach; 2) Biological variability in the lesion size and related varying levels of inflammation; 3) There are potential sources of background signals in the MSOT measurement of MMP activity: endogenous changes in ischemic tissue; MSOT system baseline noise; background by non-activated and activated probe in the circulation. In addition, the tMCAO mice, blood-brain barrier might be impaired, also as a consequence of MMP activity, leading to an accumulation of activated probe. However the background contribution appears to be negligible after multispectral analysis.
CONCLUSIONS
MSOT constitutes a potential platform for detecting lesion induced inflammatory changes in mouse models of cerebral ischemia. The study has demonstrated the feasibility of in vivo detection of MMP activity in the ischemic lesion in the mouse brain after focal cerebral ischemia. Multi-modal MSOT/MRI with MMP probe is valuable for understanding the role and time course of MMPs activity alternations after cerebral ischemia.
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